Sociedad Argentina de Endocrinologia y Metabolismo

Buenos Aires, Argentina

Sociedad Argentina de Endocrinologia y Metabolismo

Buenos Aires, Argentina
SEARCH FILTERS
Time filter
Source Type

Guitelman M.,Sociedad Argentina de Endocrinologia y Metabolismo | Alfieri A.,Sociedad Argentina de Endocrinologia y Metabolismo | Cornalo D.,Sociedad Argentina de Endocrinologia y Metabolismo | Chervin A.,Sociedad Argentina de Endocrinologia y Metabolismo | And 7 more authors.
Revista Argentina de Endocrinologia y Metabolismo | Year: 2010

Objectives: To assess the rate of any potential adverse effects on pregnancy and embryo-fetal development in women who became pregnant under treatment with cabergoline (CAB). To follow up medical data of children who were born from mothers exposed to Cab in early weeks of gestation. Material and methods: Observational, retrospective and multicenter study on 86 pregnancies in 78 women with idiopathic or tumoral hyperprolactinemia. All patients were under Cab at conception. The average age was 29 (range: 20-45). Pituitary images at diagnosis showed 44 microadenomas, 27 macroadenomas and 7 were normal. Serum PRL at baseline was between 30 and 1429 ng/ml. Duration of therapy before pregnancy ranged from 1 to 120 months. Maternal and fetal exposure to cabergoline and doses ranged from 0.125 to 4 mg/week. The mean serum PRL level under which patients achieved pregnancy was 17 ng/ml. Fetal exposure ranged from 3 to 27 weeks; 96.39% of patients received CAB during the first trimester of pregnancy and 3.61% until the second one. Results: No significant complications during pregnancy were found. Seven women (8.1%) had spontaneous abortions. Term deliveries were recorded in 63/69, preterm in six (8.8%), none of them with low weight for gestational age. Neonatal abnormalities were observed in 3 (5.2%): 1 major (Down syndrome) and 2 minor malformations (umbilical and inguinal hernia). Two out of 42, developed abnormalities during the follow- up, one of them was a refractory epilepsy during the second month of life, the other presented a Pervasive Developmental Disorder diagnosed in the third year of life. Conclusion: No significantly higher frequency of complications was found in pregnancies and/or offspring exposed to CAB than in normal population. Larger series of patients are needed to asses the safety. Copyright © 2010 por la Sociedad Argentina de Endocrinología y Metabolismo.


Stalldecker G.,Sociedad Argentina de Endocrinologia y Metabolismo | Mallea-Gil M.S.,Sociedad Argentina de Endocrinologia y Metabolismo | Guitelman M.,Sociedad Argentina de Endocrinologia y Metabolismo | Alfieri A.,Sociedad Argentina de Endocrinologia y Metabolismo | And 15 more authors.
Pituitary | Year: 2010

The aim of the study is to assess the rate of any potential adverse effects on women who became pregnant under cabergoline (CAB) treatment and to evaluate any effects on the embryo-fetal development and on children who were born from mothers exposed to CAB in early weeks of gestation. Observational, retrospective and multicenter study on 103 pregnancies in 90 women with hyperprolactinemia. All patients were under CAB at conception. Serum prolactin at baseline was between 30 and 1921 ng/ml. Duration of therapy before pregnancy ranged from 1 to 120 months and doses ranged from 0.125 to 5 mg/week. Fetal exposure ranged from 3 to 25 weeks, 96.9% of patients received CAB during the first trimester of pregnancy and the rest until the second one. No significant complications during pregnancy were found. Seven women (7.2%) had spontaneous abortions. Preterm deliveries were recorded in eight (8.8%), only one with low weight for gestational age. Neonatal abnormalities were observed in 3 (3.6%): 1 major (Down syndrome) and 2 minor malformations (umbilical and inguinal hernia). We were able to asses the children's development in 61. Two had epilepsy and two had Pervasive Developmental Disorder (PDD). No significantly higher frequency of complications was found in pregnancies and/or offspring exposed to CAB than in the normal population. We registered 2 abnormalities in the development of the children: epilepsy and PDD. Larger series of patients are needed to assess the safety of this drug during pregnancy. © 2010 Springer Science+Business Media, LLC.


Boero L.,Sociedad Argentina de Endocrinologia y Metabolismo | Manavela M.,Sociedad Argentina de Endocrinologia y Metabolismo | Danilowicz K.,Sociedad Argentina de Endocrinologia y Metabolismo | Alfieri A.,Sociedad Argentina de Endocrinologia y Metabolismo | And 14 more authors.
Pituitary | Year: 2012

The aim of our study was to evaluate two different methodologies in IGF-I levels determination, its correlation with GH nadir in OGTT <1 and <0.4 ng/ml and with clinical symptoms in acromegalic patients. We analyzed 37 patients. Sixteen patients had not undergone any kind of treatment (Group 1). Twenty-one patients underwent surgery as primary treatment, and after that, some of them another kind of treatment (except pegvisomant) (Group 2). Serum IGF-I levels were measured by Immulite- 1000 (IMM) and by an immunoradiometric assay (DSL) and, GH by immunochemiluminometric assay. IGF-I levels by IMM and by DSL showed a significant difference. When we analyzed in both groups the concordance by crosstabs-Kappa coefficients, between different parameters, GH nadir <1 and <0.4 ng/ml with IGF-I by DSL and IMM showed concordance in group 1, but in group 2 only GH nadir <1 and <0.4 ng/ml had a weak concordance with IGF-I by IMM. When we analyzed clinical symptoms in the patients and, GH nadir <1 and <0.4 ng/ml and IGF-I levels by both methodologies, more than 90% of clinically active patients had abnormal GH response or/and elevated IGF-I levels in group 1, but less than 70% in group 2. In the 8 patients under medical treatment, GH nadir was higher than 0.4 ng/ml in all patients, and IGF-I levels were elevated in 8/8 by DSL and in 6/8 by IMM. In conclusion, discrepant GH and IGF-I levels in the diagnosis and follow-up of patients with acromegaly requires consideration of many factors that influence these parameters. © Springer Science+Business Media, LLC 2011.


Mallea-Gil M.S.,Sociedad Argentina de Endocrinologia y Metabolismo | Manavela M.,Sociedad Argentina de Endocrinologia y Metabolismo | Alfieri A.,Sociedad Argentina de Endocrinologia y Metabolismo | Ballarino M.C.,Sociedad Argentina de Endocrinologia y Metabolismo | And 17 more authors.
Archives of Endocrinology and Metabolism | Year: 2016

Objetive: The aim was to assess the evolution of tumor size and prolactin (PRL) levels in patients with micro and macroprolactinomas diagnosed and treated with dopamine agonists during fertile age, and the effects of suspension of drugs after menopause. Subjects and methods: Retrospective study, 29 patients with prolactinomas, 22 microadenomas and 7 macroadenomas, diagnosed during their fertile age were studied in their menopause; treatment was stopped in this period. Age at menopause was 49 ± 3.6 years. The average time of treatment was 135 ± 79 months. The time of follow-up after treatment suspension was 4 to 192 months. Results: Pre-treatment PRL levels in micro and macroadenomas were 119 ± 57 ng/mL and 258 ± 225 ng/mL, respectively. During menopause after treatment suspension, and at the latest follow-up: in microadenomas PRL levels were 23 ± 13 ng/mL and 16 ± 5.7 ng/mL, respectively; in macroadenomas, PRL levels were 20 ± 6.6 ng/mL and 25 ± 18 ng/mL, respectively. In menopause after treatment suspension, the microadenomas had disappeared in 9/22 and had decreased in 13/22. In the group of patients whose tumor had decreased, in the latest follow-up, tumors disappeared in 7/13 and remained unchanged in 6/13. In macroadenomas, after treatment suspension 3/7 had disappeared, 3/7 decreased and 1/7 remained unchanged. In the latest control in the 3 patients whose tumor decreased, disappeared in 1/3, decreased in 1/3 and there was no change in the remaining. Conclusions: Normal PRL levels and sustained reduction or disappearance of adenomas were achieved in most of patients, probably due to the decrease of estrogen levels. Dopamine agonists might be stopped after menopause in patients with prolactinomas. © AE&M. All rights reserved.


Capecce E.,Sociedad Argentina de Endocrinologia y Metabolismo | Pelanda M.,Sociedad Argentina de Endocrinologia y Metabolismo | Dicugno M.,Sociedad Argentina de Endocrinologia y Metabolismo | De Sampaio E.G.,Sociedad Argentina de Endocrinologia y Metabolismo | And 5 more authors.
Revista Argentina de Endocrinologia y Metabolismo | Year: 2016

For many years, the clinical significance of the anti-Müllerian hormone (AMH) was limited to its critical role in foetal sexual development. However, in the last 20 years it has also emerged as a marker of ovarian function. AMH has specific functions as a regulator of follicular growth, playing its role as negative feedback signal. It may also play an important role in the regulation of the number of growing follicles (inhibiting the recruitment) as well as in their selection to be ovulated (inhibiting FSH). AMH is synthesised as a pre-pro-hormone. In the cytoplasm each monomer is cleaved, generating one N-terminal fragment: 110 KDa (pro region) and another C-terminal fragment: 25 KDa, non-covalently bound by two disulphide bridges. The C-terminal domain is bioactive, binding to the receptor, but requires the N-terminal fragment to trigger a biological response. A mixture of pro-AMH complex and C-terminal/N-terminal complex can be found in the bloodstream, which can be measured by the assays available. Several authors have shown that AMH is an early marker of the decrease and depletion of ovarian reserve. It shows a close correlation with follicular reserve and reproductive capacity more than FSH and oestradiol. This review leaves no doubt about the usefulness of AMH in the fertile phase. It has proven to be an excellent tool in characterising poor responders in assisted reproduction procedures, as an early alert in young women of a low ovarian reserve in relation to their chronological age, as well as in expressing a number of follicles in high growth, as in polycystic ovary syndrome, to avoid ovarian hyperstimulation. The growing number of patients who have decided to delay motherhood and the role of AMH in ovarian physiology has led it to an integral part of the assessment of women with impaired fertility. © 2016 Sociedad Argentina de Endocrinología y Metabolismo.


Soutelo J.,Sociedad Argentina de Endocrinologia y Metabolismo | Graffigna M.,Sociedad Argentina de Endocrinologia y Metabolismo | Honfi M.,Sociedad Argentina de Endocrinologia y Metabolismo | Migliano M.,Sociedad Argentina de Endocrinologia y Metabolismo | And 4 more authors.
Archivos Latinoamericanos de Nutricion | Year: 2012

Triglicéridos/HDL-cholesterol ratio (TG / HDL) is an easy resource determination and it has good correlation with the HOMA index in adults. Due to physiological insulin resistance (IR) in adolescence it is necessary to find markers of IR independent of age, sex and pubertal stage. The objective was to identify reference values of TG / HDL ratio in a population of adolescents without cardiovascular risk factors. We evaluated 943 adolescents, 429 females and 514 males between 11 and 14. Anthropometric measures were determined and body mass index was calculated (BMI). Blood was extracted after 12 hours of fasting to determine glucose, triglycerides, HDL. The metabolic syndrome (MS) was diagnosed according to criteria of NCEP / ATP III modified by Cook. We excluded adolescents with MS or any component of it. We evaluated 562 adolescents (289 women and 273 men) with a weight of 48.91 ± 6.51kg, BMI: 18.95 ± 1.78, systolic blood pressure of 108.12 ± 13.60 mmHg, diastolic blood pressure: 63.82 ± 9.43 and waist circumference: 65.09 ± 4.54cm. TG / HDL ratio was 1.25 ± 0.43, with a 95 percentile of 2.05. In adults, TG / HDL ratio greater than 3 is a marker of insulin resistance. We believe that a higher value to 2.05 might be a good index of insulin resistance in adolescence. TG / HDL ratio has the advantage of being methodologically simpler, more economical and independent of pubertal stage.

Loading Sociedad Argentina de Endocrinologia y Metabolismo collaborators
Loading Sociedad Argentina de Endocrinologia y Metabolismo collaborators